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Here, we evaluate protocol requirements to mimic therapeutically relevant drug concentrations at 
the site of infection (i.e. lung lesion) in an in-vitro hollow fibre model of infection using pulmonary 
tuberculosis as a paradigm. Steady-state pharmacokinetic profiles in plasma, lung tissue and lung 
lesion homogenate were simulated for isoniazid, rifampicin and pyrazinamide and moxifloxacin. An 
R-shiny User Interface was developed to support conversion of in-vivo pharmacokinetic cMAX, tMAX 
and t1/2 estimates into pump settings. A monotherapy protocol mimicking isoniazid in lung lesion 
homogenate (isoniazid CMAX = 1,200 ng/ml, TMAX = 2.2 hr and T1/2 = 4.7 hr), and two combination therapy 
protocols including drugs with similar (isoniazid and rifampicin (CMAX = 400 ng/ml)) and different 
half-lives (isoniazid and pyrazinamide (CMAX = 28,900 ng/ml and T1/2 = 8.0 hr)) were implemented 
in a hollow-fiber system. Drug levels in the perfusate were analysed using ultra-high-performance 
liquid chromatographic-tandem mass spectrometric detection. Steady state pharmacokinetic 
profiles measured in the hollow fiber model were similar to the predicted in-vivo steady-state lung 
lesion homogenate pharmacokinetic profiles. The presented approach offers the possibility to use 
pharmacological data to study the effect of target tissue exposure for drug combinations. Integration 
with pharmacokinetics modelling principles through a web interface will provide access to a wider 
community interested in the evaluation of efficacy of anti-tubercular drugs.
The predictive value of nonclinical research for antimicrobial drug combinations, such as for tuberculosis, 
depends on how realistic experimental protocols reflect in-vivo conditions (e.g. nutrition, oxygen, drug expo-
sure). This implies that experimental conditions must be tailored to the in-vivo disease conditions to ensure 
accurate translation of the findings. Whilst the use of the hollow fiber systems is not new, detailed research pro-
tocols are not readily available and it remains unclear whether such factors have been considered when results 
are reported in the literature. Of note are the challenges associated with regimens including drugs with differ-
ent pharmacokinetic characteristics (e.g. different distribution, peak concentrations and different elimination 
half-lives) which need to be mimicked simultaneously within the experimental infection protocol using a single 
in one hollow fiber system. This oversight can have major implications for the dose rationale as well as the identi-
fication of suitable companion or partner compounds for combination therapy1,2.
This is relevant as combination therapy is common practice in the treatment of many infectious diseases, and 
essential in tuberculosis3. Yet, antibiotic combination regimens and doses have been based on empirical evidence 
of efficacy and safety. Attempts have been made to evaluate pharmacokinetics (drug concentration vs. time pro-
files) and pharmacodynamics (e.g. effect on mycobacterial load) in-vivo at the site of infection. However, experi-
mental limitations make it difficult to fully characterise the concentration-effect relationship of each drug as well 
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as their interaction when used as combination therapy. Serial pharmacokinetic and pharmacodynamic data may 
be difficult to obtain in a clinical setting and pulmonary tuberculosis is a good example of just such a challenging 
disease entitity. Data at lung lesions/granuloma level can usually only be obtained during a lung resection and not 
routinely due to the invasive nature of the procedure4–6.
Serial sampling for pharmacokinetics and pharmacodynamics could be achieved using the in-vitro hollow 
fiber model of infection7. Such protocols may enable the evaluation of a wide range of drug exposures8, mimick-
ing drug concentrations likely to occur at the site of infection. This would be useful for novel antimicrobial com-
pounds and combinations in pre-clinical stages and as a method to explore the efficacy of existing antimicrobial 
compounds being evaluated at different doses or in different combinations9.
The use of hollow fiber has been qualified by the EMA and the FDA as a technique that has value in the 
pre-clinical setting as complementary tool to existing anti-tuberculosis research methods7,10. As such, the method 
can be used to evaluate a variety of compounds in monotherapy or in differing combinations, allowing for a more 
comprehensive characterisation of bacterial killing effects based on factorial designs which remain rather com-
plex, if not impossible, to conduct in-vivo11.
This investigation reports the protocol requirements to mimic therapeutically relevant drug concentrations 
at the site of infection (i.e. lung lesions). We have selected standard of care compounds (isoniazid, rifampicin, 
pyrazinamide and moxifloxacin) due to their clinical relevance and availability of pharmacokinetic and biopsy 
data5. We make the necessary settings and procedures available through a web-based application to the wider 
community.
Materials and Methods
In-vivo pharmacokinetic profiles. Steady-state total concentrations of isoniazid, rifampicin, pyrazi-
namide, and moxifloxacin were simulated using compartmental population pharmacokinetic models 
(Supplementary Material), which mimicked exposure profiles in plasma, lung tissue homogenate and lesion 
homogenate after standard oral doses (i.e. daily 600 mg rifampicin [450 mg for patients less than 50 kg in body 
weight], 300 mg isoniazid, 1500 mg pyrazinamide, and 400 mg moxifloxacin). A virtual population of 2,000 
patients was simulated according to reported body weight distributions12. This sample size allowed us to evaluate 
the pharmacokinetic characteristics of the study drugs taking into account the covariate effects (i.e., body weight). 
For rifampicin, pyrazinamide and moxifloxacin 20 replicates of a virtual South Korean patient population of 100 
patients were deemed sufficient to capture the overall variability in drug levels. For isoniazid, 20 replicates of a 
virtual population of 250 patients were used to ensure allocation of approximately 10% slow metabolisers across 
each body weight group13. Rifampicin auto-induction was accounted for by multiplying clearance estimates from 
a single dose model14 by a factor of 1.85. Geometric mean and 95% prediction intervals from the simulations 
were derived and visualised. Drug distribution from the systemic circulation to the site of infection was evalu-
ated by comparing the ratio of lung/plasma exposure (Rtissue/plasma and Rlesion/plasma) for isoniazid, rifampicin and 
pyrazinamide or rate-constants ktissue-plasma, kplasma-tissue, klesion-plasma and kplasma-lesion for moxifloxacin (see appendix 
for further details).
R Shiny web application. An R-shiny web application, was developed (https://pkpdia.shinyapps.io/hfs_
app/) to facilitate the conversion of in-vivo pharmacokinetic profiles into in-vitro pump settings in the hollow 
fiber system. The application supports the generation of pharmacokinetic profiles after monotherapy and com-
bination therapy by converting key pharmacokinetic parameters CMAX, TMAX and T1/2 into pump settings using a 
published method running at the back end15.
The pump rate for the diluent, elimination, and titration reservoir (including scenarios in which two drugs 





, where t1/2 represents the elimination half-life 
of the study drug and Vsystem represents the hollow fiber system volume (i.e. central reservoir, cartridge and tubes). 
Drug amounts required to mimic a certain CMAX were calculated by: CMAX × Vsystem where CMAX represents the 





tMAX is the time associated with CMAX. Simultaneous simulation of a short and a long half-life drug in the in-vitro 
hollow fiber was achieved by topping up the amount in the long half-life drug in the diluent reservoir (i.e. serial 
setting) or by an additional reservoir (i.e. parallel setting). Subsequently, the pump-rate settings from the dilution 
reservoir were adjusted accordingly in order to ensure that the Rdilution reservoir + Rtitration reservoir was identical to 
Relimination reservoir (Fig. 1).
In-vitro pharmacokinetic profiles. Pump settings for three antibiotics, which are commonly used as part 
of the standard tuberculosis treatment combination, were calculated by a web-application (https://pkpdia.shin-
yapps.io/hfs_app/) assuming a total system volume of 75 ml. Pharmacokinetic profile characteristics in lung 
lesions (i.e. CMAX, TMAX and T1/2) for the three antibiotic drugs, based on standard dosing regimens, were selected 
and accounted for plasma protein binding (i.e. 42% for isoniazid, 83% for rifampicin and 10% for pyrazina-
mide)16. Three experimental conditions were tested. One monotherapy experiment with isoniazid at 
CMAX = 1,200 ng/ml, TMAX = 2.2 hour and T1/2 = 4.7 hour was conducted. A combination therapy experiment with 
similar half-life drugs was conducted using isoniazid at CMAX = 1,200 ng/ml and rifampicin at CMAX = 400 ng/ml 
with TMAX = 2.2 hour and T1/2 = 4.7 hour. Lastly, a combination therapy experiment with two drugs showing dif-
ferent half-lives was conducted using isoniazid at CMAX = 1,200 ng/ml, TMAX = 2.2 hour and T1/2 = 4.7 hour and 
pyrazinamide at CMAX = 28,900 ng/ml, TMAX = 2.2 hour and T1/2 = 8.7 hour. All experiments were performed 
under uninfected conditions at 37 °C. Rifampicin and pyrazinamide TMAX were set to isoniazid TMAX in order to 
avoid an overly complex experimental setup even though clinical rifampicin and pyrazinamide TMAX are different. 
Rifampicin T1/2 was harmonised to isoniazid to serve an example of an experiment of drugs with similar half-lives 
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and TMAX and T1/2 values were derived based on the pharmacokinetic model for isoniazid. Subsequent experi-
mental dilution mistakes in the solution to be infused into the central reservoir (i.e. 10, 100 and 2-fold for isonia-
zid, rifampicin and pyrazinamide), only affecting CMAX, were accounted for as the pump settings were correctly 
set and therefore TMAX and T1/2 remained unaffected. The mean Prediction Error (MPE) was calculated 




i i1 ) with the dependent variable (DV) and model predictions (IPRED) as numerical meas-
ure of bias of the pharmacokinetic profiles generated in the hollow fiber model of infection. The MPE was used 
together with visual inspection to assess how well the in-vitro pharmacokinetic profiles approximated the dashed 
line that represented those generated by the user. The simulated in-vivo lung lesion homogenate profiles for a 
typical patient with 95%-prediction intervals, taking into account plasma protein binding, were overlaid to ensure 
that the simulated in-vitro profiles fell within the prediction intervals. For isoniazid a typical patient with a clear-
ance at the lower end of the distribution, at 13.1 l/hr, was used to mimic a slow metaboliser17.
The integrated hollow fiber experimental protocol comprised a FiberCell Systems Duet pump with a cellulosic 
cartridge (medium sized – C3008). Drugs were dissolved in 1 ml broth and infused into the central reservoir to 
mimic an oral absorption profile using a NE-4000 Programmable 2 Channel Syringe Pump. Flow rates, to gen-
erate in-vivo mimicking drug elimination profiles, were controlled using a Masterflex C/L Dual-Channel Pump 
and Masterflex SC0033-LT Tygon E-Lab ext tubing. Samples (2 ml) were taken just before drugs were added to 
the experiment and 2.2, 5, 8 and 24 hours after, both from the central reservoir and from the extra-capillary space 
of the cartridge (Fig. 1).
Ultra-high-performance liquid chromatographic-tandem mass spectrometric detection of ana-
lytes. Bioanalysis of drug concentrations was performed by chromatographic separation and mass spectrometric 
detection of three analytes using Acquity ultra-high-performance liquid chromatography (UPLC) system equipped 
with Waters TQ Detector (Waters, Milford, USA). The UPLC system consists of a binary solvent manager, a sample 
manager and a column thermostat. ESI-MS detection was carried out in positive ion detection mode. The assay 
was linear (r2 > 0.993) for isoniazid and rifampicin over the concentration range from 10 ng/mL to 10,000 ng/mL 
and from 10 ng/mL to 50,000 ng/mL for pyrazinamide. An appropriate dilution scheme was used for sample analy-
sis to match the calibration concentrations. Detailed description on the sample preparation and a LC-MS/MS assay 
is presented in the Appendix section; Quantification of analytes in-vitro pharmacokinetic profiles.
Results
In-vivo pharmacokinetic profiles. Simulations using the population pharmacokinetic models for isonia-
zid, rifampicin and pyrazinamide displayed rapid distribution from the plasma into healthy lung tissue homoge-
nate and lung lesion homogenate. It also suggested that lower exposure in the lung tended to remain within 
variability of the plasma data (Fig. 2). Total drug concentrations in the lung tissue and lung lesion homogenate 
are lower for isoniazid (9.3% [RSE: 23.5%] and 29.8% [RSE: 21.7%]), rifampicin (24.8% [RSE: 15%] and 52.2% 
[RSE: 13%]) and pyrazinamide (37.2% [RSE: 7%] and 36.8% [RSE: 8%]) as compared to plasma concentrations 
(Appendix Table 1). Unlike isoniazid, rifampicin and pyrazinamide, simulations of the profiles of moxifloxacin 
revealed a nearly doubled elimination half-life in lung tissue and lung lesion homogenate as compared to plasma. 
This resulted from a substantially faster distribution and diffusion of total moxifloxacin concentrations from 
Figure 1. Schematic representation of a hollow fiber protocol mimicking exposure to drug combinations at 
the site of infection. Grey boxes and dashed lines represent top-up reservoirs and tubing for experiment for the 
implementation of an experiment with two drugs showing different elimination half-lifes.
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plasma to lung tissue (k24 = 1.584 h−1 [37.3% RSE]) or lung lesion (k25 = 0.633 h−1 [79.8% RSE]) as compared to 
the re-distribution and clearance from lung tissue (k42 = 0.314 h−1 [50.1% RSE]) or lung lesion (k52 = 0.318 h−1 
[73.3% RSE]) back to the plasma (Appendix Table 1). The geometric mean ± 1.96 SD of the simulated steady 
state profiles displayed in Fig. 2 show the between patient variability, which was determined primarily by the 
plasma data as time series data for lung tissue or lesion homogenate were not available (Appendix Fig. 1). Detailed 
information about the population pharmacokinetic model development and performance are summarised in the 
appendix (Appendix Table 1 and Fig. 1).
Facilitating modelling of pharmacokinetic profiles in-vitro. The web application was used to convert 
secondary pharmacokinetic parameter estimates CMAX, TMAX and T1/2 into pump settings to mimic lung lesion 
homogenate exposure taking into account protein binding. We have evaluated three antibiotics from the stand-
ard tuberculosis treatment combination, including isoniazid, isoniazid plus rifampicin (i.e. same half-lives) and 
isoniazid plus pyrazinamide (i.e. different half-lives) (Table 1). Prior to TMAX was reached (in all experiments) 
drugs were infused using a zero-order process into the central reservoir and after TMAX was reached flow rates 
between the diluent and central reservoir, and central and elimination reservoirs were set at an identical rate. The 
pharmacokinetic profiles of pyrazinamide (half-live 8.02 hour) and isoniazid (half-live 4.7 hour) were considera-
bly different and this could be adjusted for through a serial top up setting (Fig. 1). The flow rate between the serial 
top-up reservoir and diluent reservoir was equal to the flow rate between the diluent reservoir and the central 
reservoir (Table 1). For the example with drugs showing similar half-lives, top-up reservoirs (neither serial nor 
parallel) were needed (Table 1). The in-vitro pharmacokinetic profiles, accounted for protein binding, tended to 
show over prediction for isoniazid and rifampicin at the last sampling time point. However, the general trend for 
the three experiments was acceptable and remained within the prediction intervals for lung lesion homogenate 
(Fig. 3). The isoniazid MPE was −178, −20.6, and −18.1 ng/ml for the monotherapy, rifampicin combination 
therapy and pyrazinamide combination therapy experiment, respectively. The rifampicin and pyrazinamide MPE 
Figure 2. Simulated steady-state total isoniazid, rifampicin, pyrazinamide and moxifloxacin in plasma, lung 
tissue and lesion homogenate. Solid black lines represent the geometric mean of 2,000 simulated patients. 
Shaded areas represent the 95% prediction intervals.
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was −37.9 and −1397 ng/ml, respectively. All three drugs displayed adequate penetration of the fibres yielding 
similar exposure in the central reservoir and extra-capillary space (Fig. 3).
Discussion
In this paper we report an in-vitro hollow fiber model of infection integrated with a pharmacokinetic model as a 
tool for the evaluation of target tissue exposure. Given the complexity of incorporating organ and plasma dispo-
sition data into a pharmacokinetic model and implications for infusion rates and titration steps, a user interface 
was also developed. This interface provides a simple way for investigators to use the hollow fiber in their own 
investigations.
The In-vitro pharmacokinetic profiles for lung lesion homogenate generated in the hollow fiber system fell 
within the intervals predicted by the population pharmacokinetic models taking into account plasma protein 
binding in-vivo. The in-vitro pharmacokinetic profiles generally followed the simulated in-vivo steady-state lung 
lesion homogenate profiles. However, a trend of higher in-vitro generated concentrations was observed for the 
later measurements of isoniazid and rifampicin, as compared to the web-application based simulations (Fig. 3). 
The discrepancies could probably be attributed to the variability in the peristaltic pump and sampling handling. 
Reproducibility of pharmacokinetic profiles (i.e. between experiment variability) was acceptable, as isoniazid 
levels in all three experiment were comparable. One way to account for between lab/setup variability, in addition 
to ensuring accurate calibration of the pumps, is to analyse the in-vitro pharmacokinetic profiles in conjunction to 
bacterial load level data from the same experimental protocol. Simultaneous modelling of pharmacokinetic and 
pharmacodynamic data may be especially beneficial when experimental variability is a concern.
In order to avoid over complicating the experimental setup with series of syringe drivers at different infusion 
rates we have simulated drug levels that correspond to the terminal elimination phase, even though isoniazid 
displays bi-phasic disposition pharmacokinetics in-vivo. This resulted in a monophasic pharmacokinetic profile 
in-vitro. Future experiments may consider more realistic scenarios, including repeated rifampicin dosing, which 
displays auto-induction. Whilst more complex, these scenarios imply further modification of the pump setting 
during the course of the experiment. Furthermore, our method allowed to standardise TMAX for companion drugs 
to the treatment backbone, i.e. in this example rifampicin and pyrazinamide were coupled to the same value of 
TMAX of isoniazid to simplify the experimental setup. Although in-vivo oral absorption is a first order process, 
for simplification we have adopted an experimental setup for in-vitro oral absorption with a zero-order infusion.
Mimicking representative environmental parameters remains key for the interpretation of data arising from 
the hollow-fiber model for mycobacterial infections. In the current study, we did not include the contribution of 
the inoculum as factor to be considered, but the approach proposed here can be used with different drugs and any 
other aspect of an experimental infection protocol. Moreover, tuberculosis for example has three metabolic states, 
the log-phase, acid-phase and non-replicative persister phenotype-phase which all tend to reside in different 
environments. An acid-phase organism often stays within the macrophage whereas the non-replicative persister 
phenotype-phase tends to reside in the caseum, which renders the environmental pH important. This can be 
modelled in the hollow-fibre model of infection by modifying the broth, oxygen levels in the incubator, flow rates 
and adding macrophages. However, this also has implications for drug levels to be simulated. When one uses 
homogenate levels it is not possible to distinguish and quantify intra- and extra-cellular levels. It is also difficult 
to assess whether drug levels were similar in the caseum or at the edges of the lesion.
Serial in-vivo exposure vs. time data remains key to inform dose selection for experimental protocols using 
the hollow fiber system. Drug level data is, however, often quantified as total drug concentrations (i.e. protein 
unbound plus protein-bound) even though it remains questionable whether total drug levels are the most suit-
able metrics for further characterisation of pharmacokinetic-pharmacodynamic relationships. Depending 
on the mechanism of action, possibly free drug concentrations at the site of infection might be more relevant 
Parameter Isoniazid Isoniazid -rifampicin Isoniazid -pyrazinamide
CMAX isoniazid (ng/ml)* 1,200 1,200 1,200
CMAX companion drug (ng/ml)* — 400 28,900
TMAX (hour) 2.15 2.15 2.15
T1/2 isoniazid (hour) 4.7 4.7 4.7
T1/2 companion drug (hour) — 4.7 8.02
Flow rate dilution/serial top-up/elimination 
reservoir (ml/min) 0.18 0.18 0.18
Flow rate dilution/serial top-up/elimination 
reservoir start time (min) 129 129 129
Amount isoniazid (ug) 90 90 90
Amount companion drug (ug) — 30 2,168
Syringe infusion rate isoniazid (ug/min) 0.70 0.70 0.70
Syringe infusion rate companion drug (ug/min) — 0.23 16.8
Amount companion drug serial top-up reservoir (ug) — — 4,247
Dilution/serial top-up reservoir (ml) 265 265 265
Table 1. Overview of secondary parameter conversions into pump setting for selected hollow fiber 
experiments. *Accounted for protein binding.
6Scientific RepoRtS |         (2019) 9:13228  | https://doi.org/10.1038/s41598-019-49556-5
www.nature.com/scientificreportswww.nature.com/scientificreports/
for the antibacterial activity, e.g., rifampicin that prevents Mycobacterium tuberculosis to grow by inhibiting 
DNA-dependent RNA synthesis18. However, unlike in plasma, little6 or no in-vivo information is available on 
drug protein binding or non-specific tissue binding at the site of infection in patients (i.e. lung lesions in the case 
of pulmonary tuberculosis). Total homogenate concentrations could also be misleading in that it does not rep-
resent a demarcated physiological compartment, hence in homogenates all cell boundaries have been destroyed, 
which results in mixed intra- and extra-cellular concentrations19. Often, as only total drug concentrations are 
available, assumptions are required to conduct a hollow-fiber experiment to ensure other factors such as protein- 
and/or tissue-drug binding are taken into consideration. First, one could assume that due to poor vascularisation 
of the lung lesion the equilibrium of free drug between plasma and lung lesions is impaired. A best guess for this 
scenario is complex, if not impossible, as free drug levels at lung lesion homogenate would be needed. To evaluate 
this scenario in the current study, total lesion homogenate concentrations were used, after correction for plasma 
protein binding. Another scenario would assume that free drug can cross the blood vessel and cell membranes 
yielding free drug concentrations in plasma and lung lesion to be in equilibrium. However, this assumption 
might not be representative of necrotic foci of the lesion. Alternatively, physiochemical characteristics could be 
taken into account (e,g, sum of the hydrophobicity and number of aromatic rings), to describe drug distribu-
tion and binding to caseum20. In fact, very similar fractions of unbound drug in plasma and caseum for isoni-
azid, rifampicin and pyrazinamide, were found in in-vitro experiments mimicking caseum and lung lesion and 
homogenate from rabbits. These findings seem in agreement with our results. Clearly, the scenario in this study 
where total lesion homogenate concentrations is used might lack translational value, but one needs to acknowl-
edge that each of the alternative proposed methods also have their drawbacks. Only ex-vivo microdialysis data 
may provide information on free drug levels at the site of infection, although this type of data is rarely available6.
It is important to highlight that assumptions will have to be made on the drug concentration vs. time profiles 
when the hollow fiber system is used to evaluate novel antibiotic drug combinations for which human pharma-
cokinetic data is unavailable. Lung lesion drug levels from animal experiments can and should be used in these 
circumstances. Alternatively, when only plasma level data are available in healthy subjects, predictions of lesion 
and tissue exposure may be considered using physiochemical properties and physiological-based pharmacoki-
netic models20.
Figure 3. Overview of in-vitro pharmacokinetic profiles obtained in the hollow fiber system for isoniazid 
monotherapy, isoniazid + rifampicin combination therapy and isoniazid + pyrazinamide combination therapy. 
Data relflect drug levels after correction for plasma protein binding. Circles and triangles in the concentration 
vs. time profile plots (top panels) represent single samples in the central reservoir and extra capillary space 
concentrations, respectively. Dashed lines represent the predicted in-vitro pharmacokinetic profiles obtained by 
the user interface, which is required for the selection of the pump settings. Shaded areas and solid lines in the 
concentration vs. time profile plots (top panels) represent the geometric mean and 95%-predicition intervals of 
a typical profile in humans. The bottom panels show the drug concentrations in the central reservoir and extra 
capillary space in the hollow fiber system.
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In summary, we have shown how pharmacokinetic profiles of drugs combinations in humans can be repro-
duced in the hollow fiber system, mimicking drug levels at the target tissue. We have created an R-shiny interface 
for other users. Our approach offers an opportunity for drug combinations to be evaluated more thoroughly in 
the early phases of drug development eliminating some of the uncertainties that limit the evaluation of relevant 
doses during clinical trials.
Data Availability
Data generated and analysed during the current study are available from the corresponding author on reasonable 
request.
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